Skip to main content

CAPITAL FUND MANAGEMENT S.A.

Position in NBIX — Neurocrine Biosciences Inc

CIK 1323645 PARIS, I0

Position in NBIX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$16,536,639
-$3,175,748 QoQ
Shares Held
98,117
-34.4% QoQ
Ownership
0.097%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#123
of 768 holders
Holding Since
Mar 2020
14 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in NBIX Over Time

Shares Held

Position Value (USD)

Derivatives in NBIX

reported options exposure · as of Mar 31, 2020
CallValue
$657,780
CallShares
7,600
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

CAPITAL FUND MANAGEMENT S.A. holds $95,675,665 across 11 Drug Manufacturers - Specialty & Generic names. NBIX ranks #3 (17.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
3 NBIX
Neurocrine Biosciences Inc
This page
98,117 $16,536,639

All Filings in NBIX

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $16,536,639 98,117
2026-03-31 $19,712,387 149,631
2025-12-31 $11,364,128 80,125
2025-09-30 $17,365,567 123,704
2025-06-30 $25,594,003 203,628
2025-03-31 $19,425,894 175,641
2024-12-31 $14,267,526 104,524
2024-09-30 $12,855,325 111,572
2024-06-30 $7,840,444 56,951
2021-03-31 $5,860,868 60,266
2020-12-31 $1,903,293 19,857
2020-09-30 $2,179,658 22,667
2020-06-30 $2,359,236 19,338
2020-03-31 $2,046,301 23,643
2020-03-31 $657,780 7,600